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cAvidin Ltd., Szeged, HungaryAbstract—Microglial activation results in profound morpho-
logical, functional and gene expression changes that aﬀect
the pro- and anti-inﬂammatory mechanisms of these cells.
Although statins have beneﬁcial eﬀects on inﬂammation,
they have not been thoroughly investigated for their ability
to aﬀect microglial functions. Therefore the eﬀects of
rosuvastatin, one of the most commonly prescribed drugs
in cardiovascular therapy, either aloneor in combinationwith
bacterial lipopolysaccharide (LPS), were proﬁled in pure
microglial cultures derived from the forebrains of 18-day-
old rat embryos. To reveal the eﬀects of rosuvastatin on a
number of pro- and anti-inﬂammatory mechanisms, we per-
formed morphometric, functional and gene expression stud-
ies relating to cell adhesion and proliferation, phagocytosis,
pro- and anti-inﬂammatory cytokine (IL-1b, tumor necrosis
factor a (TNF-a) and IL-10, respectively) production, and the
expression of various inﬂammation-related genes, including
those related to the abovemorphological parameters and cel-
lular functions. We found that microglia could be an impor-
tant therapeutic target of rosuvastatin. In unchallenged
(control) microglia, rosuvastatin inhibited proliferation and
cell adhesion, but promoted microspike formation and ele-
vated the expression of certain anti-inﬂammatory genes
(Cxcl1, Ccl5, Mbl2), while phagocytosis or pro- and anti-
inﬂammatory cytokine production were unaﬀected. More-
over, rosuvastatin markedly inhibited microglial activation
in LPS-challenged cells by aﬀecting both their morphology
and functions as it inhibited LPS-elicited phagocytosis and
inhibited pro-inﬂammatory cytokine (IL-1b, TNF-a) produc-
tion, concomitantly increasing the level of IL-10, an anti-http://dx.doi.org/10.1016/j.neuroscience.2015.11.053
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47inﬂammatory cytokine. Finally, rosuvastatin beneﬁcially
and diﬀerentially aﬀected the expression of a number of
inﬂammation-related genes in LPS-challenged cells by
inhibiting numerous pro-inﬂammatory and stimulating sev-
eral anti-inﬂammatory genes. Since the microglia could elicit
pro-inﬂammatory responses leading toneurodegeneration, it
is important to attenuatesuchmechanismsandpromoteanti-
inﬂammatoryproperties, anddevelopprophylactic therapies.
By beneﬁcially regulating both pro- and anti-inﬂammatory
microglial functions, rosuvastatin may be considered as a
prophylactic agent in the prevention of inﬂammation-related
neurological disorders.  2015 The Authors. Published by
Elsevier Ltd. on behalf of IBRO. This is an open access article
under theCCBY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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INTRODUCTION
Microglia, the main immune cells in the central nervous
system (CNS), are derived from the monocyte/macrophage
lineage (Ginhoux et al., 2010). They play important roles
in both physiological and pathophysiological conditions
such as traumatic injury, stroke, ischemia or neurodegen-
erative diseases (Kreutzberg, 1996). In response to activa-
tion, the microglia transform from a resting state to an
activated form, during which profound morphological and
functional changes take place, such as process retraction,
proliferation, phagocytosis and cytokine expression
(Gehrmann et al., 1995; Kreutzberg, 1996; Hanisch, 2002;
Luo and Chen, 2012). Although such anti-inﬂammatory
mechanisms are essential in protecting the CNS, activated
microglial cells can also be harmful to neurons by eliciting
neuroinﬂammation that could lead to neurodegeneration
(Banati et al., 1993; Gehrmann et al., 1995; Gonzalez-
Scarano and Baltuch, 1999; Streit, 2002; Graeber, 2010;
Gresa-Arribaset al., 2012;Ghoshet al., 2013). InAlzheimer’s
disease (AD), for example, the microglia produce pro-
inﬂammatory factors such as interleukin-1b (IL-1b) around
the amyloid plaques, and these factors may themselves
become important components of theADpathology because
of their ability to increase the expression of amyloid precursor
protein (Cordle and Landreth, 2005; Ghosh et al., 2013).
Accumulating evidence indicates that a sequence of
events contributes to the development and progression
of AD, including oxidative stress, inﬂammation, and
altered cholesterol metabolism (Gamba et al., 2015).
Oxidative stress may be crucial in the development ofons.org/licenses/by-nc-nd/4.0/).
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link connecting peripheral hypercholesterolemia to altered
cholesterol metabolism in the brain (Gamba et al., 2015).
Cholesterol modulates the processing of amyloid precur-
sor protein and the production of b-amyloid peptides
(Shobab et al., 2005), while removing cholesterol amelio-
rates the production these peptides in animal models
(Bodovitz and Klein, 1996; Simons et al., 1998).
Statins (3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors) are the agents of ﬁrst choice for
the treatment of high cholesterol levels (Taylor et al.,
2013). Although their main eﬀects are related to the lipid
metabolism (inhibition of cholesterol synthesis, reduction
of the levels of low-density lipoproteins and triglycerides,
and stimulation of the expression of high-density lipopro-
teins), they also strongly modulate inﬂammatory cells
around atherosclerotic plaques (Wierzbicki et al., 2003;
Burg and Espenshade, 2011). Apart from their therapeu-
tic use in cardiovascular diseases, statins may also have
beneﬁcial eﬀects in the CNS (Zipp et al., 2007; van der
Most et al., 2009; Famer et al., 2010) as animal studies
have demonstrated that statins attenuate neuroinﬂamma-
tion (Zelcer et al., 2007) and reduce senile plaques and
inﬂammatory responses (Kurata et al., 2012).
Interestingly, in spite of being an obvious target for
statins, microglial cells have not been at the focus of
statin research. There have only been a few studies to
demonstrate that under in vitro circumstances the
microglia respond to statins such as atorvastatin and
simvastatin (Lindberg et al., 2005; Nakamichi et al.,
2006). In the present study, we investigated the eﬀects
of rosuvastatin, the most widely used and arguably the
most eﬀective statin (Nissen et al., 2006; Nicholls et al.,
2011), on cultured pure microglia cells derived from mixed
cultures of 18-day-old embryonic (E18) rat forebrains
under control (unstimulated) and bacterial lipopolysac-
charide (LPS)-stimulated conditions (Nakamura et al.,
1999; Lund et al., 2006; Gresa-Arribas et al., 2012). To
reveal the eﬀects of rosuvastatin on a number of
pro- and anti-inﬂammatory mechanisms, we performed
morphometric, functional and gene expression studies
relating to cell adhesion and proliferation, phagocytic
capability, pro- and anti-inﬂammatory cytokine (IL-1b,
tumor necrosis factor a (TNF-a) and IL-10, respectively)
production, and the expression of various inﬂammation-
related genes, including those related to the above mor-
phological parameters and cellular functions.EXPERIMENTAL PROCEDURES
Animals
All animal experiments were carried out in strict
compliance with the European Council Directive
(86/609/EEC) and EC regulations (O.J. of EC No. L
358/1, 18/12/1986) regarding the care and use of
laboratory animals for experimental procedures, and
followed the relevant Hungarian and local legislation
requirements. The experimental protocols were
approved by the Institutional Animal Welfare Committee
of the University of Szeged (I-74-II/2009/MA´B). The
pregnant Sprague–Dawley rats (45 rats, 170–190 g)were kept under standard housing conditions and fed
ad libitum.Antibodies
For a thorough characterization of diﬀerent microglial
phenotypes developed in vitro, an antibody against
ionized calcium-binding adaptor molecule 1 (Iba1), an
intracellular actin- and Ca2+-binding protein expressed
in the CNS speciﬁcally in macrophages and microglia
(Ahmed et al., 2007), was used in our immunocytochem-
ical and Western blot analyses. The anti-glyceraldehyde
3-phosphate dehydrogenase (GAPDH) antibody was
used as an internal control in Western blot experiments
(Wu et al., 2012). Dilutions of primary and secondary anti-
bodies, and also incubation times and blocking conditions
for each antibody used were carefully tested for both
immunocytochemistry and Western blot analysis. To
detect the speciﬁcities of the secondary antisera, omis-
sion control experiments (staining without the primary
antibody) were performed. In such cases, no ﬂuorescent
or Western blot signals were detected.Cell cultures
Pure microglial cells were isolated from mixed primary
cortical cell cultures of rat embryos of either sex by the
method we described earlier (Szabo and Gulya, 2013).
Sibling embryos obtained from the same pregnancy were
processed for culturing together; each pregnancy was
considered as an independent experiment. Brieﬂy,
10–12 fetal rats (E18) under anesthesia were decapitated
and the frontal lobe of the cerebral cortex was removed,
minced with scissors, incubated in 9 ml Dulbecco’s Modi-
ﬁed Eagle’s Medium (DMEM; Invitrogen, Carlsbad, USA)
containing 1 g/l D-glucose, 110 mg/l Na-pyruvate, 4 mM
L-glutamine, 3.7 g/l NaHCO3, 10,000 U/ml penicillin G,
10 mg/ml streptomycin sulfate, 25 lg/ml amphotericin B
and 0.25% trypsin for 10 min at 37 C, and then cen-
trifuged at 1000g for 10 min at room temperature (RT).
The pellet was resuspended and washed twice in 5 ml
DMEM containing 10% heat-inactivated fetal bovine
serum (FBS; Invitrogen) and centrifuged for 10 min at
1000g at RT. The ﬁnal pellet was resuspended in 2 ml
DMEM/10% FBS, after which the cells were plated in
the same medium on a poly-L-lysine-coated culture ﬂask
(75 cm2, 12  106 cell/ﬂask) and cultured at 37 C in a
humidiﬁed air atmosphere supplemented with 5% CO2,
in one or other of the following ways: (1) in poly-L-lysine-
coated coverslips (15  15 mm; 2  105 cells/coverslip)
for immunocytochemistry; (2) in poly-L-lysine-coated Petri
dishes (60 mm  15 mm; 4  105 cells/dish) for Western
blot analyses and enzyme-linked immunosorbent assay
(ELISA) studies; or (3) in a poly-L-lysine-coated culture
ﬂask (75 cm2, 12  106 cells/ﬂask) for the subsequent
generation of pure microglial cell cultures.
Secondary microglial cells were subcloned from
mixed primary cultures (DIV7) maintained in a poly-L-
lysine-coated culture ﬂask (75 cm2, 12  106 cells/ﬂask)
by shaking the cultures at 100 rpm in a platform shaker
for 30 min at 37 C. Cultures from the same pregnancy
were kept separate. Microglia from the supernatant
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RT and resuspended in 2 ml DMEM/10% FBS. The cells
were seeded at a density of 4  105 cells/Petri dish for
Western blots or 2  105 cells/coverslip/Petri dish for
immunocytochemistry, proliferation or phagocytosis
assays, and cultured in DMEM in a humidiﬁed
atmosphere supplemented with 5% CO2 at 37 C. The
medium was changed on the ﬁrst day after seeding
(subDIV1). Immunocytochemistry routinely performed on
the pure microglial cultures four days after seeding
(subDIV4) consistently detected a >99% incidence of
the Iba1-immunopositive microglial cells for the Hoechst
33258 dye-labeled cell nuclei.Cell culture treatments
On the fourth day of subcloning (subDIV4), DMEM was
replaced and the expanded pure microglial cells were
treated for 24 h with either LPS (20 ng/ml ﬁnal conc.,
dissolved in DMEM; Sigma, St. Louis, MO, USA) or
rosuvastatin (1 lM ﬁnal conc., dissolved in sterile,
distilled water; Santa Cruz Biotechnology, Inc., Dallas,
TX, USA) alone, or with a combination of LPS
+ rosuvastatin, and the eﬀects were compared in a
variety of morphological and functional tests. LPS
treatment served as an immunochallenge. Four types of
treatment regimens were used: (1) control
(unchallenged and untreated) cultures; (2) LPS-
challenged cultures received 20 ng/ml LPS; (3)
rosuvastatin-treated cultures were stimulated with 1 lM
rosuvastatin; (4) LPS-challenged + rosuvastatin-treated
cultures received both drugs in the indicated doses.
Depending on the experiments, the treatments lasted for
6, 24 or 72 h at 37 C.Cell adhesion and proliferation
To measure changes in cell adhesion and proliferation
and cell viability, the ACEA Real-Time Cell Analysis
(RTCA) system and 16-well E-Plates (Acea
Biosciences, Inc., San Diego, CA, USA) were used.
This system measured the electrical impedance of the
cells expressed as cell index in real time. Brieﬂy,
4  105 pure microglial cells in poly-L-lysine-coated Petri
dishes were plated as described above. On the fourth
day of culturing, the cells were trypsinized, centrifuged
as above and seeded into gelatin-coated 16-well
E-Plates at a density of 6000 cells per well. Test doses
of LPS and rosuvastatin, either alone or in combination,
were added to the wells before plating. After
equilibration at RT for 10 min, the E-plate was loaded
into the RTCA machine and the cell index was
measured continuously for 60 h using the cell
microelectronic sensing technique with the xCELLigence
real-time cell analysis system (RTCA DP; Acea
Biosciences) as we published earlier (Ozsva´ri et al.,
2010). Cell indices at 24 h were analyzed for comparison
with cell proliferation data. Data analysis was carried out
with the system’s dedicated software (RTCA Software
1.2; Acea Biosciences) and Excel (Microsoft Corp., Red-
mond, WA, USA). To estimate the number of surviving/
proliferating microglial cells after treatments, the cultureswere washed twice with 2 ml phosphate-buﬀered saline
(PBS) to remove cell debris, treated with 0.25% trypsin
solution for 10 min at 37 C, collected and counted in a
Burker cell counting chamber. The number of viable cells
was presented as mean ± S.D.Immunocytochemistry
Pure microglial cultures treated with diﬀerent treatment
regimens were ﬁxed on coverslips with 4%
formaldehyde for 5 min and rinsed with 0.05 M PBS for
2  5 min. After permeabilization and blocking of the
nonspeciﬁc sites in 0.05 M PBS solution containing 5%
normal goat serum (Sigma), 1% heat-inactivated bovine
serum albumin (Sigma) and 0.05% Triton X-100 for
30 min at 37 C, the cells on the coverslips were
incubated overnight in a humidiﬁed chamber at 4 C
with rabbit anti-Iba1 polyclonal antibody (1:500 ﬁnal
dilution; Wako, Japan), a microglia-speciﬁc actin-binding
protein, in the above solution as we described
previously (Szabo and Gulya, 2013). The cultured cells
were washed for 4  10 min at RT in 0.05 M PBS, and
then incubated with the Alexa Fluor 568 ﬂuorochrome-
conjugated goat anti-rabbit antibody (1:1000 ﬁnal dilution;
Invitrogen) in the dark for 3 h at RT. The cells on the cov-
erslip were washed for 4  10 min in 0.05 M PBS at RT,
and the nuclei were stained in 0.05 M PBS solution
containing 1 mg/ml polyvinylpyrrolidone and 0.5 ll/ml
Hoechst 33258 dye (Sigma). The coverslips were rinsed
in distilled water for 5 min, air-dried and mounted on
microscope slides in Vectashield mounting medium (Vec-
tor Laboratories, Burlingame, CA, USA). Cells were
viewed on a Nikon Microphot-FXA epiﬂuorescent micro-
scope (Nikon Corp., Tokyo, Japan) and photographed
with a Spot RT Color CCD camera (SPOT RT/ke,
Diagnostic Instruments, Inc., Sterling Heights, MI, USA).Western blot analysis
Cultured microglial cells (subDIV4) were collected
through use of a rubber policeman, homogenized in
50 mM Tris–HCl (pH 7.5) containing 150 mM NaCl,
0.1% Nonidet P40, 0.1% cholic acid, 2 lg/ml leupeptin,
1 lg/ml pepstatin, 2 mM phenylmethylsulfonyl ﬂuoride
and 2 mM EDTA, and centrifuged at 10,000g for 10 min.
The pellet was discarded and the protein concentration
of the supernatant was determined (Lowry et al., 1951).
For the Western blot analyses, 5–10 lg of protein was
separated on an SDS polyacrylamide gel (4–10% stack-
ing gel/resolving gel), transferred onto Hybond-ECL nitro-
cellulose membrane (Amersham Biosciences, Little
Chalfont, Buckinghamshire, England), blocked for 1 h in
5% nonfat dry milk in Tris-buﬀered saline (TBS) contain-
ing 0.1% Tween 20, and incubated overnight with either
a rabbit anti-Iba1 polyclonal antibody (1:1000 ﬁnal dilu-
tion; Wako) or a mouse anti-GAPDH monoclonal antibody
(clone GAPDH-71.1; 1:20,000 ﬁnal dilution; Sigma). After
ﬁve rinses in 0.1% TBS–Tween 20, the membranes were
incubated for 1 h with the peroxidase-conjugated goat
anti-rabbit secondary antibody (1:2000 ﬁnal dilution; Invit-
rogen) for Iba1 or with the peroxidase-conjugated rabbit
anti-mouse secondary antibody (1:2000 ﬁnal dilution;
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as before. The enhanced chemiluminescence method
(ECL Plus Western blotting detection reagents; Amersham
Biosciences) was used to reveal immunoreactive bands
according to the manufacturer’s protocol.In vitro phagocytosis
The ﬂuid-phase phagocytotic capabilities of the control
and variously treated pure microglial cell cultures were
determined via the uptake of ﬂuorescent microspheres
(carboxylate-modiﬁed polystyrene beads, ﬂuorescent
yellow-green (kex 470 nm; kem 505 nm), aqueous
suspension, 2.0 lm mean particle size; L4530, Sigma)
as we described previously (Szabo and Gulya, 2013).
Unstimulated (control) and LPS-stimulated pure microglial
cell cultures (subDIV4) with or without rosuvastatin were
tested for 24 h. At the end of the treatment period, 1 ll
of a 2.5% aqueous suspension of ﬂuorescent micro-
spheres per ml was added to the culture, which was then
incubated for 60 min at 37 C. The cells were next washed
ﬁve times with 2 ml of PBS to remove dish- or cell surface-
bound residual ﬂuorescent microspheres, and ﬁxed with
4% formaldehyde in PBS. In another setup, we also deter-
mined the number of microglial cell membrane-associated
but not phagocytosed beads. Such negative controls were
treated as above with the exception that microglial cul-
tures with beads were incubated for 60 min at 4 C. At this
temperature, the number of beads associated with cell
surface averaged less than 1 bead per 100 Iba1-labeled
cells, thus the phagocytosis was not considered signiﬁ-
cant. For measurement of the phagocytotic activity, cells
labeled with phagocytosed microbeads and processed
for Iba1 immunocytochemistry were counted in 20
random ﬁelds in each treatment group (mean ± S.D.)
under a 20 or 40 objective. Statistically signiﬁcant
diﬀerences were determined by a two-way ANOVA.Determination of IL-1b, IL-10 and TNF-a
For ELISA assays, the supernatants were collected from
each treatment and stored at 20 C. Concentrations of
IL-1b, IL-10 and TNF-a were measured with rat-speciﬁc
ELISA kits (eBioscience, Vienna, Austria). The
sensitivity of IL-1b (Cat# BMS630), IL-10 (Cat#
BMS629) and TNF-a (Cat#BMS622) assays was
4 pg/ml, 1.5 pg/ml and 11 pg/ml, respectively. As stated
by the manufacturer, the overall intra- and interassay
coeﬃcients of variation were <10% in both cases for
IL-1b and TNF-a, and <5% in both cases for IL-10.RNA isolation
Total RNA from control and treated pure microglial cells
was puriﬁed as described previously (Fabian et al.,
2011); columns and wash buﬀer were from Bioneer (Viral
RNA extraction kit; Daejon, South Korea). Brieﬂy, cells
were washed with PBS, incubated in lysis buﬀer (RA1;
Macherey-Nagel, Du¨ren, Germany), then collected and
mixed with 70% ethanol in RNase-free water (Bioneer).
The mixture was transferred through columns (Bioneer)
and washed with 350 ll 80% ethanol in diethylpyrocarbonate-treated water, and then with 600 ll and
300 ll W2 wash buﬀer (Bioneer). Total RNA was eluted
in 50 ll RNase free-water. One ll RNase inhibitor
(Applied Biosystems, Foster City, CA, USA) was added
to the samples. The quality and quantity of the isolated
RNA were measured with NanoDrop1000 Version 3.8.1.
(Thermo Scientiﬁc, Budapest, Hungary).
RNA expression
Reverse transcription from 3 lg of total RNA in 30 ll was
performed with the High-Capacity cDNA Archive Kit
(Applied Biosystems) according to the manufacturer’s
protocol. cDNA was diluted to 80 ll. The instrumentation
included the Bravo automatic liquid handling system
(Agilent Technologies, Inc., Santa Clara, CA, USA) for
polymerase chain reaction (PCR) assay preparation and
a LightCycler 1536 System (Roche Diagnostics Corp.,
Indianapolis, IN, USA) or a Light Cycler Nano
Instrument (Roche) for cycling (Woudstra et al., 2013).
The expression of 116 inﬂammation-related genes,
together with that of six control genes (see below), was
measured with Universal Probe Library assays using
intron-spanning gene-speciﬁc primers (Rat Immune
Panel; Avidin Ltd., Szeged, Hungary, www.avidin-
biotech.com/services/gene-expression) and the LightCy-
cler 1536 DNA Probe Master kit (Roche). Moreover, the
expression of certain phagocytosis-related genes such
as the integrin-associated protein or cluster of diﬀerentia-
tion 47 (Cd47, NM_019195_2), the engulfment or cell
motility protein (Elmo1, NM_001108415.1), the scavenger
receptor class B member 1 (Scarb1, NM_031541_1), the
plasminogen activator inhibitor-1 (Serpine1,
NM_012620_1), the signal-regulatory protein a (Sirpa,
NM_013016_2) and the vesicle-associated membrane
protein 7 (Vamp7, NM_053531_1) were also analyzed,
by the Light Cycler Nano Instrument. For the 1536 Sys-
tem, each 2 ll PCR reaction contained 8 ng of cDNA,
0.4 ll Lightcycler DNA Probes Master (5), the corre-
sponding primer set and UPL probe and the Setup Con-
trol. The PCR cycling protocol was as follows: enzyme
activation at 95 C for 60 s, 50 cycles of denaturation at
95 C for 0 s, and annealing and extension at 60 C for
30 s. For the Nano Instrument, each 20 ll PCR reaction
contained 20 ng cDNA, 10 ll Lightcycler DNA Probes
Master (5), the corresponding primer set and UPL probe
and the Setup Control. The PCR protocol was as follows:
enzyme activation at 95 C for 10 min, 50 cycles of denat-
uration at 95 C for 15 s, and annealing and extension at
60 C for 30 s. Gene expression was normalized to the
average values of clathrin, heavy chain (Cltc,
NM_019299.1), glyceraldehyde-3-phosphate-dehydrogen
ase (Gapdh, M17701.1), glucuronidase, beta (Gusb,
NM_017015.2), hypoxanthine phosphoribosyltransferase
1 (Hprt1, NM_012583.2), phosphoglycerate kinase 1
(Pgk1, NM_053291.3), and tubulin, beta 5 class I (Tubb5,
NM_173102.2) expression as endogenous controls and
expressed relative to the unstimulated controls by using
the 2DDCt method. A total of 122 gene-speciﬁc assays
were run on four independent samples from each condi-
tion. Student’s t-test and a two-way ANOVA were applied
for the analysis of signiﬁcance where p< 0.05 was
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and visualization, the Hierarchical Clustering Explorer
(v3.0) software was used (publicly available at http://
www.cs.umd.edu/hcil/multi-cluster/hce3.html). The com-
plete linkage clustering method was applied with Eucli-
dean distance metric.Image analysis and statistics
Digital images were captured by a Nikon Microphot-FXA
epiﬂuorescent microscope (Nikon Corp., Tokyo, Japan),
using a Spot RT Color CCD camera and the Spot RT
software (Spot RT/ke Diagnostic Instruments, Sterling
Heights, MI, USA). For the determination of microglial
cell purity, Hoechst 33258-labeled cell nuclei that
belonged to Iba1-immunopositive cells were counted on
coverslip-cultured samples. For each culture, 50–100
randomly selected microscope ﬁelds were analyzed. In
every case, the cultures had, on average, at least 99
Iba1-positive somata for 100 Hoechst 33258-labeled
cell nuclei (>99% purity for microglial cells).
Phagocytosed microspheres on 20 randomly sampled
microscope ﬁelds from three coverslips for each
treatment regimen were counted with the use of the
computer program ImageJ (version 1.47; http://rsb.info.
nih.gov/ij). For the measurement of area (lm2),
perimeter (lm) and transformation index (TI), Iba1-
immunoreactive microglial cell images were converted
into binary replicas by using thresholding procedures
implemented by ImageJ and Adobe Photoshop CS5.1
software (Adobe Systems, Inc., San Jose, CA, USA)
as published by Szabo and Gulya (2013). TI was deter-
mined according to Fujita et al. (1996) by using the fol-
lowing formula: [perimeter of cell (lm)]2/4p [cell area
(lm2)]. Color correction and cropping of the light micro-
scopic images were performed when photomicrographs
were made for publication and assembled for a panel.
Gray-scale digital images of the immunoblots were
acquired by scanning the autoradiographic ﬁlms with a
desktop scanner (Epson Perfection V750 PRO; Seiko
Epson Corp., Japan). The images were scanned and
processed at identical settings to allow comparisons of
the Western blots from diﬀerent samples. The bands
were analyzed through the use of ImageJ. The
immunoreactive densities of equally loaded lanes were
quantiﬁed, and all samples were normalized to the inter-
nal GAPDH load controls.
All statistical comparisons were made by using R
3.1.0 for Windows (The R Foundation for Statistical
Computing; Wirtschafts-Universita¨t, Wien, Austria).
Results were analyzed with a two-way ANOVA, and the
Bonferroni correction was used to establish signiﬁcance
between groups. Values were presented as mean ± S.
D.; p< 0.05 was considered signiﬁcant; *, ** and ***
denote p< 0.05, p< 0.01 and p< 0.001, respectively.RESULTS
Rosuvastatin aﬀects microglial morphology
The morphological changes elicited by rosuvastatin in
unchallenged (control) and LPS-challenged puremicroglia cultures were documented through the use of
Iba1 immunocytochemistry (Fig. 1A–D) and quantitatively
analyzed on binary silhouettes of individual microglial
cells (Fig. 2A–G). Iba1 protein expression was also
monitored during treatments (Fig. 1E). Most of the
unchallenged and untreated (control) microglia displayed
ameboid morphology with TI < 3; they had a
predominantly ameboid shape, occasionally with small
pseudopodia (Figs. 1A and 2A). When administered
alone for 24 h, rosuvastatin induced the formation of
numerous microspikes (Figs. 1B and 2B); these slender
cytoplasmic projections (ﬁlopodia) resulted in signiﬁcantly
increased perimeter and TI values of these cells (Fig. 2F,
G). Quantitative analysis showed that the average TI in
this group increased about 10-fold, to above 19, as
compared with the controls (Fig. 2G). The LPS challenge
did not result in any signiﬁcant morphometric change
(Figs. 1C and 2C, E–G). However, rosuvastatin treatment
in LPS-challenged cells resulted in a signiﬁcantly
enlarged and more ramiﬁed cell form (TI > 7) with a
much larger perimeter value as compared with their
respective control values (Figs. 1D and 2D, E–G),
indicating that rosuvastatin profoundly antagonized the
morphological changes characteristic of LPS-induced
microglial activation. In relation to the substantially
increased size of the LPS-challenged and rosuvastatin-
treated microglia (Figs. 1D and 2D, E), their Iba1
immunoreactivity was also signiﬁcantly increased
(Figs. 1E and 2E).Rosuvastatin inhibits proliferation and cell adhesion
in both unchallenged and LPS-challenged microglia
Rosuvastatin signiﬁcantly inhibited cell proliferation in
both unchallenged and LPS-challenged cultures, by
47.8% and 68.9%, respectively, after a 24-h treatment
period (Fig. 3A). We used a 16-well E-Plate-based real-
time analysis to determine whether rosuvastatin aﬀects
cell adhesion. Rosuvastatin inhibited cell adhesion in
both unchallenged (control) and LPS-challenged
microglia (Fig. 3B). The diﬀerences in levels of inhibition
of cell adhesion between cultures with or without
rosuvastatin (unchallenged and LPS-challenged
microglia vs. rosuvastatin-treated and LPS-challenged
+ rosuvastatin-treated microglia) were signiﬁcant by
20 h of culturing and thereafter, probably due to the
signiﬁcantly larger cell populations in the control and
LSP-challenged microglial cultures as compared with
those in the rosuvastatin or LPS + rosuvastatin-treated
cultures (Fig. 3B), and to the ability of rosuvastatin to
stimulate the formation of microspikes (Fig. 2B, D), i.e.
the actin-based ﬁlamentous protrusions implicated in the
cell motility, and consequently in the decreased
adhesion of these cells.Rosuvastatin reduces phagocytotic activity in
LPS-challenged cells
The microglial function is inherently related to its
phagocytotic activity. In pure microglial cultures
(subDIV4), the control (unchallenged and untreated)
microglia exhibited a low level of ﬂuid-phase
Fig. 1. Rosuvastatin aﬀects microglial cell morphology and Iba1 immunoreactivity in pure microglial cells after various treatments. Pure microglia
cell cultures (subDIV4) were maintained as described in Experimental procedures. (A–D) Representative ﬂuorescent immunocytochemical pictures
demonstrate the typical cellular distribution of Iba1 immunoreactivity (red) in (A) control (unchallenged and untreated), (B) rosuvastatin-treated, (C)
LPS-challenged and (D) LSP-challenged + rosuvastatin-treated microglial cells. The eﬀects of rosuvastatin in unchallenged and LSP-challenged
microglia were the most marked. Hoechst 33258-labeled cell nuclei are shown in blue. Scale bar in A (for all pictures): 50 lm. (E) Quantitative
Western blot analysis of Iba1 and GAPDH immunoreactivities in pure microglial cell cultures. Protein samples from the cultures were separated by
gel electrophoresis, transferred to nitrocellulose membranes and probed with either the Iba1 or the GAPDH antibody. Gray-scale digital images of
the immunoblots were acquired by scanning the autoradiographic ﬁlms with a desktop scanner. The images were scanned and processed at
identical settings to allow comparisons between the Western blots from diﬀerent samples. Error bars indicate integrated optical density values
(mean ± SD) normalized to the internal standard GAPDH. Representative Western blot pictures are shown below the graphs. Data were analyzed
with a two-way analysis of variance (ANOVA). *p< 0.05, **p< 0.01. (For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)
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Fig. 2. Quantitative analysis of microglial morphology in pure microglial cell cultures after various treatments. Pure microglial cell cultures (subDIV4)
were maintained as described in the Experimental procedure. (A–D) Iba1-positive microglial cells from pure microglial cultures (subDIV4) were
photographed, the pictures were digitized and the morphological characteristics were quantitatively analyzed on binary silhouettes of unchallenged
(A), rosuvastatin-treated (B), LPS-challenged (C) and LCS-challenged + rosuvastatin-treated (D) microglia. Four representative binary silhouettes
are shown for each culturing protocol. Scale bar for all silhouettes: 50 lm. Area (E) in lm2, perimeter (F) in lm, and TI values (G), calculated as
[perimeter of cell (lm)]2/4p[cell area (lm2)], are indicated for each digitized cell. Unchallenged and untreated (control) cells, similarly to LPS-
challenged cells, displayed a typical ameboid morphology with low TI values. Rosuvastatin aﬀected the morphology of both the control and the LPS-
challenged microglia (B, D). In unchallenged cultures, it promoted microspike formation with a concurrent slight ramiﬁcation of the cells (B). In the
LPS-challenged + rosuvastatin-treated cultures (D), the microglia became larger and, while retaining microspikes, also developed thicker
processes. Both the rosuvastatin treatment alone and the combined treatment with LPS resulted in larger perimeter (F) and higher TI values (G) as
compared with both the unchallenged and the LPS-challenged cultures. (E) Average area (in lm2± S.D.) measurements for cultured pure
microglial cells. (F) Average perimeter (in lm± S.D.) measurements for cultured pure microglial cells. (G) Average TI values (± S.D.) for cultured
pure microglial cells. LPS: 20 ng/ml; rosuvastatin: 1 lM. For (E–G), error bars indicate mean ± SD of six replicate measurements from three
independent culturings. Data were analyzed with a two-way analysis of variance (ANOVA). **p< 0.01; ***p< 0.001.
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Fig. 3. Rosuvastatin inhibits cell proliferation and decreases cell adhesion. Pure microglial cultures (subDIV4) were maintained and treated as
described in Experimental procedures section. (A) After culturing, the cells were collected and the number of surviving microglia was determined
with a Bu¨rker chamber. Rosuvastatin, in both unchallenged and LPS-challenged cultures, inhibited cell proliferation and displayed a strong anti-
mitotic characteristic. LPS treatment did not aﬀect cell proliferation. (B) Real-time monitoring of microglial cell adhesion after diﬀerent treatment
regimens. The ACEA Real-Time Cell Analysis (RTCA) system and 16-well E-Plates were used to determine cell indices as described in
Experimental procedures section. Normalized cell index values are plotted as a function of time. In both unchallenged and LPS-challenged cells,
rosuvastatin decreased cell adhesion (blue and red lines, respectively). Error bars indicate mean ± SD of six replicate measurements from three
independent culturings. Data were analyzed with a two-way analysis of variance (ANOVA). **p< 0.01; ***p= 0.001. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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beads per cell (n= 91). Rosuvastatin did not aﬀect the
phagocytosis appreciably (Fig. 4B, E), the number of
phagocytosed microbeads remaining low (2.70 ± 1.7;
n= 50). As expected, the LPS challenge increased the
phagocytotic activity of the microglial cells signiﬁcantly
(Fig. 4C, E). On average, the LPS-challenged cells
accumulated 25.39 ± 11.4 beads per cell (n= 70), and
some of the cells engulfed as many as 40 microbeads.
In the LPS-challenged microglia, however, rosuvastatin
inhibited the phagocytosis drastically, by nearly 80%
(Fig. 4D, E) as the ﬂuid-phase phagocytotic activity was
returned close to the level of the control cells (4.67
± 3.9 microbeads per cell; n= 88). As activated
microglial cells often damage neuronal tissue, such a
strong inhibition of a pro-inﬂammatory action by
rosuvastatin could be beneﬁcial in preventing or
ameliorating neurodegeneration.Rosuvastatin concomitantly decreases
pro-inﬂammatory and increases anti-inﬂammatory
cytokine levels
Activated microglia are known to express several pro- and
anti-inﬂammatory cytokines, while statins are able to
reduce the inﬂammatory eﬀect in the vicinity of
atherosclerotic plaques. We therefore expected
rosuvastatin to regulate the amount of cytokines
released by the microglia. Indeed, when the basal levels
of the pro-inﬂammatory cytokines IL-1b and TNF-a and
the anti-inﬂammatory cytokine IL-10 in unchallenged
microglia were compared with the levels from
rosuvastatin-treated LPS-challenged or unchallenged
cells, a unique regulatory pattern emerged (Fig. 5). The
basal level for IL-1b in unchallenged (control) microglia
was 15.00 ± 5.6 pg/ml (Fig. 5A). Rosuvastatin did not
change this level signiﬁcantly (9.56 ± 13.1 pg/ml). As
expected, a 24 h-long LPS challenge signiﬁcantlyelevated the IL-1b level in the activated microglia, to
156.05 ± 63.0 pg/ml. However, when added together
with LPS, rosuvastatin signiﬁcantly inhibited the
development of this elevated IL-1b level, by about 45%,
to 86.25 ± 49.3 pg/ml. A similarly strong eﬀect of
rosuvastatin was demonstrated on the level of TNF-a,
another pro-inﬂammatory cytokine, in LPS-challenged
microglial cells (Fig. 5B). Two diﬀerent treatment times
(6 h and 24 h) were used as the TNF-a production
responded quickly to the LPS challenge. The level of
TNF-a in the unchallenged (control), rosuvastatin-
treated microglia could not be detected, but its level
quickly rose, to 906.80 ± 281.7 pg/ml in the LPS-
challenged cells after 6 h, and the level was still robust
after 24 h (188.19 ± 38.6 pg/ml). When rosuvastatin
was co-administered to LPS-challenged cells for either
6 h or 24 h, it signiﬁcantly inhibited the production of
TNF-a, by 39% and 40%, respectively (Fig. 5B).
Moreover, rosuvastatin aﬀected the production of
IL-10, an anti-inﬂammatory cytokine (Fig. 5C). The basal
and rosuvastatin-treated levels of IL-10 in the
unchallenged microglia were not signiﬁcantly diﬀerent
(37.01 ± 18.4 pg/ml vs. 75.32 ± 35.4 pg/ml), although
elevated IL-10 production was noted after rosuvastatin
treatment. Interestingly, LPS increased the IL-10 protein
expression signiﬁcantly to about 340% of the level of the
unchallenged microglia (125.3 ± 25.3 pg/ml pg/ml).
When rosuvastatin was co-administered with LPS, it
boosted the IL-10 protein expression even higher, to
about 750% of the basal level (276.84 ± 85.6 pg/ml),
indicating the very strong anti-inﬂammatory action of
rosuvastatin.Rosuvastatin aﬀects the expression of
inﬂammation-related genes
When the profound morphological and functional eﬀects
of rosuvastatin on the pro- and anti-inﬂammatory
Fig. 4. Rosuvastatin is a potent inhibitor of phagocytosis. Pure microglial cultures (subDIV4) were maintained and treated with ﬂuorescent
microbeads (2 lm in diameter) as described in Experimental procedures section. Iba1-speciﬁc ﬂuorescent immunocytochemistry (red: microglia;
blue: nucleus; green: microspheres) on unchallenged (A), rosuvastatin-treated unchallenged cells (B), LPS-challenged cells (C) and LPS-
challenged + rosuvastatin-treated microglial cells (D) revealed that rosuvastatin inhibited phagocytosis in both naive, unchallenged (B) and LPS-
challenged cells (D). Scale bar in A (for all pictures) = 50 lm. (E) Quantitative analysis of the number of phagocytosed microbeads revealed that
LPS dramatically activated phagocytosis, while rosuvastatin when present signiﬁcantly decreased this microglial function. Error bars indicate mean
± SD of six replicate measurements from three independent culturings. Data were analyzed with a two-way ANOVA. *p< 0.05, ***p< 0.001. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
D. Kata et al. / Neuroscience 314 (2016) 47–63 55capabilities of the microglia had become apparent, we
set out to analyze the eﬀects of rosuvastatin on the
expression of 122 inﬂammation-related genes in
unchallenged and LPS-challenged pure microglial cells.
The hierarchical cluster analysis of 75 such genes is
summarized in Fig. 6, and the genes with 47 of the
most noteworthy and signiﬁcant expression changes in
response to treatment are listed in Table 1. The results
of the analysis indicated that treatment with 1 lM
rosuvastatin in unchallenged and LPS-challenged
microglia could induce either the upregulation or thedownregulation of a number of genes. Levels of
expression of selected inﬂammation-related genes (for
example, Ccl24, Ccr1, IL-11, Cxcl1, Ccl4, Ccl5, Hspb1,
TGFb-2 and Mbl2) are highlighted in Fig. 7. Some of
these genes responded to rosuvastatin in unchallenged
or challenged cells, or were aﬀected by the LPS
challenge. The genes upregulated by the LPS challenge
included those coding for chemokine ligands 1, 2, 4, 5,
9, 19 and 24 (Cxcl1= 111.6-fold, Ccl2= 34.5-fold,
Ccl4= 17.6-fold, Ccl5= 147.0-fold, Cxcl9= 118.2-
fold, Ccl19= 5.2-fold and Ccl24= 24.6-fold), IL-11
Fig. 5. Rosuvastatin reduces the pro-inﬂammatory cytokine IL-1b and TNF-a levels and increases the anti-inﬂammatory IL-10 production. Pure
microglial cultures (subDIV4) were maintained and treated as described in Experimental procedures section. After treatments for 6 or 24 h,
immunoreactive protein levels (pg/ml ± S.D.) for IL-1b (A), TNF-a (B) and IL-10 (C) were detected by ELISA. TNF-a production was measured after
6 h and 24 h (B). As expected, pro-inﬂammatory cytokine production was signiﬁcantly increased in the LPS-challenged cells (A, B). Rosuvastatin
was a potent inhibitor of this eﬀect for both IL-1b (A) and TNF-a (B). The level of the anti-inﬂammatory cytokine IL-10 was measured after 24 h (C).
Rosuvastatin slightly increased the level of IL-10 both in unchallenged and in LPS-challenged microglia, to 750% of the control level in the latter
case (C). Error bars indicate mean ± S.D. of six replicate measurements from three independent culturings. Data were analyzed with a two-way
ANOVA. n.d. = not detected. *p< 0.05; **p< 0.01; ***p< 0.001.
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and mannose-binding lectin (protein C) two receptor
(Mbl2=33.2-fold). Only a few genes were downregulated
by the LPS challenge, the most aﬀected one being that of
the myosin regulatory light chain 2 (Myl2=4.4-fold).
Rosuvastatin treatment in unchallenged cells aﬀected
fewer, but similarly important microglial genes involved in
pro- and anti-inﬂammatory processes. The genes
upregulated by rosuvastatin included Cxcl1 (7.0-fold;
Fig. 7D), the anti-inﬂammatory Ccl5 (6.6-fold; Fig. 7F),
and, most importantly, Mbl2 (126.2-fold; Fig. 7I), a
crucial factor in the development of innate immunity
(Worthley et al., 2005). Rosuvastatin was in general a
weak inhibitor of the expression of inﬂammatory genes
as it downregulated only a few genes, notably the anti-
inﬂammatory interleukin-10 (Il10= 4.0-fold) and the
pro-inﬂammatory chemokine (C–C motif) receptor 1
(Ccr1= 2.9-fold). When rosuvastatin was applied to
LPS-challenged cultures (Table 1, Figs. 6 and 7), a more
complex picture emerged. Some of the LPS-upregulated
genes were inhibited by rosuvastatin, as seen in the case
of Ccl24, where a substantial, 377% decrease in gene
expression was observed, down from the 24.5-fold
increase after LPS treatment to a 6.5-fold increase
(Fig. 7A), or in the case of Ccr1, where a 198% decrease
in gene expression was detected (Fig. 7B). Interestingly,
rosuvastatin alone did not exhibit a strong eﬀect on these
latter genes, but only when activated by LPS (Fig. 7C, D).
Other genes were regulated synergistically by rosuvas-
tatin when applied to LPS-challenged microglia. For
example, Cxcl1 and Ccl4 were both further upregulated
by rosuvastatin in LPS-challenged cells (Fig. 7D, E).
Some of the genes related to inﬂammation were not
aﬀected by the LPS challenge, but reacted weakly to
rosuvastatin, as seen in Hspb1 gene expression
(Fig. 7G, H), where a 2.8-fold increase was detected.DISCUSSION
We carried out a quantitative investigation of the complex
morphological, functional and gene expressioncharacteristics of pure microglial cells of embryonic
origin after rosuvastatin treatment in unstimulated and
LPS-challenged cultures, and highlighted the complex
beneﬁcial eﬀects of rosuvastatin that make it an
excellent candidate for preventive neuroinﬂammatory
therapy with well-balanced properties of enhanced anti-
inﬂammatory and subdued pro-inﬂammatory eﬀects.
Although microglial cells prepared from embryonic
nervous tissue may diﬀer from those of the adult brain
in certain characteristics (Floden and Combs, 2006), they
are nevertheless similarly responsive to immunological
(LPS) challenge and suitable for morphological, functional
and gene expression studies. When activated, the micro-
glia display both pro- and anti-inﬂammatory properties as
they can be polarized along a continuum toward a detri-
mental (M1) or a beneﬁcial (M2) state in the injured
CNS (Kroner et al., 2014). Inﬂammation that is mediated,
and perhaps enhanced, by the microglia has been impli-
cated in a number of neuropathological conditions, rang-
ing from acute injuries (Loane and Byrnes, 2010) and
chronic inﬂammatory conditions (Gay, 2007; Napoli and
Neumann, 2010) to neurodegenerative diseases (Long-
Smith et al., 2009; Prokop et al., 2013).
Statins are commonly used in the treatment of high
blood cholesterol levels (Burg and Espenshade, 2011).
They are classiﬁed on the basis of their lipid-lowering eﬃ-
cacy and their lipophilic/hydrophilic nature (Hamelin and
Turgeon, 1998; Jones et al., 1998; Davidson, 2002;
Schachter, 2005); while lipophilic statins penetrate the cell
membrane, hydrophilic statins such as rosuvastatin
(Crestor; AstraZeneca Pharmaceuticals, LP, Wilmington,
DE, USA) are transported through the blood–brain barrier
via multiple transporters (Kitamura et al., 2008; Abbott
et al., 2010; Ellis et al., 2013) or ATP-binding cassette
eﬄux transporters in microglia (Gibson et al., 2012).
Rosuvastatin exhibits the greatest inhibitory eﬀect on
cholesterol biosynthesis (McTaggart et al., 2001) and
most favorably alters the high-density lipoprotein proﬁle
among statins (Asztalos et al., 2007); it was the fourth
highest-selling prescription drug in the USA in 2013
(http://www.drugs.com/stats/top100/2013/sales).
Fig. 6. Hierarchical cluster analysis of inﬂammation-related genes.
Pure microglial cultures (subDIV4) were maintained and treated as
described in Experimental procedures section. The cells (subDIV4)
were cultured with or without LPS for 24 h in the presence or absence of
rosuvastatin. Rosuvastatin: 1 lM; LPS: 20 ng/ml; LPS+ rosuvastatin:
LPS (20 ng/ml) + rosuvastatin (1 lM). For hierarchical cluster analysis
and visualization, the Hierarchical Clustering Explorer (v3.0) software
was used. The complete linkage clustering method was applied with
Euclidean distance metric. The heat map depicts expression values
relative to control samples on a log2 scale (overexpression: red,
repression: green and no change: black). Missing values are indicated
in gray. (For interpretation of the references to colour in this ﬁgure
legend, the reader is referred to the web version of this article.)
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sis, other eﬀects of statins, including those on the regres-
sion of atherosclerotic coronary lesions, are also
important (Wierzbicki et al., 2003). Expecting similarly
beneﬁcial eﬀects on the microglia, we determined how
rosuvastatin modulates both pro- and anti-inﬂammatory
actions by aﬀecting numerous morphological, functional
and gene expression parameters in pure microglial cul-
tures. These cultures provide a unique opportunity to
study these functional and expression parameters without
the signiﬁcant inﬂuence of any contaminating cell types.
Our secondary microglial cultures were >99% pure, a
crucial factor when levels of secreted pro- and anti-
inﬂammatory peptides or gene expression levels are mea-
sured, as other cell types in the CNS are also capable of
expressing such peptides (Gruol et al., 2014).
Our studies revealed the eﬀects of rosuvastatin on
various quantitative morphological properties of the
microglia. Rosuvastatin aﬀected the area, perimeter and
TI profoundly in both unchallenged and LPS-challenged
cells. It generally promoted microspike formation and
increased the cell perimeter and TI through ramiﬁcation.
Concomitantly with the increase in cell area in both
unchallenged and LPS-challenged cells, rosuvastatin
aﬀected the protein synthesis of Iba1, a protein that is
implicated in actin cytoskeleton remodeling (Sasaki
et al., 2001; Ohsawa et al., 2004). As expected, LPS
treatment caused microglia activation that resulted in a
low TI, but the combined treatment with LPS + rosuvas-
tatin inhibited this activation through the development of
microspikes and the cells becoming more ramiﬁed.
Rosuvastatin strongly inhibited microglia proliferation
and adhesion as it signiﬁcantly decreased the number of
cells in both naı¨ve and LPS-challenged cultures.
Although the precise mechanisms are not known, statins
are able to inhibit mitosis through cell cycle arrest in G1
(Yang et al., 2008) and G2/M (Gao et al., 2012). As rosu-
vastatin displays a weak anti-mitogenic eﬀect, its regular
use may prove helpful in lowering the risks of a number
of cancer types (Simon et al., 2012). To quantify cell adhe-
sion, we used the cell index value (Atienza et al., 2005;
Jarvis et al., 2011). Our ﬁnding that rosuvastatin lowered
cell adhesion in both unchallenged and LPS-challenged
cells is in harmony with previous reports on the ability of
statins to decrease the expression of cell adhesion mole-
cules (Weber et al., 1997; Wierzbicki et al., 2003).
We also examined how rosuvastatin altered ﬂuid-
phase phagocytosis. Phagocytosis is crucial in both the
normal and the pathologic CNS as it eﬃciently
eliminates foreign materials, apoptotic cells and cell
debris (Kettenmann et al., 2011), and alteration of this
clearance function could be harmful (Hickman and El
Khoury, 2014; Lue et al., 2015). For example, pro-
inﬂammatory phenotypes are linked to the phagocytic
activity, and the blocking of phagocytosis may prevent
some forms of inﬂammatory neurodegeneration, and
might therefore be beneﬁcial during infection, trauma,
ischemia, neurodegeneration and aging (Neher et al.,
2011; He et al., 2014). LPS is a strong activator of micro-
glial phagocytosis (Nakamura, 2002; Lund et al., 2006;
Szabo and Gulya, 2013). In our study, rosuvastatin
Table 1. Diﬀerentially expressed transcripts in rosuvastatin-treated pure microglial cells with or without LPS challenge
Gene Name, NCBI reference sequence ID, RGD ID Rosuvastatin LPS LPS+ Rosuvastatin
Cxcl1 Chemokine ligand 1 (melanoma growth-stimulating activity, alpha)
NM_030845.1, RGD ID 619869
+7.05 +111.55 +394.01
Csf3 Colony-stimulating factor 3
NM_017104.1 (old), NM_017104.2, RGD ID 2426
+2.9 +310.7 +321.7
Il23r Interleukin 23 receptor
XM_001072576.2, RGD ID 1586368
+2.12 +246.56 +268.81
Ccl5 Chemokine ligand 5
NM_031116.3, RGD ID 69069
+6.56 +146.97 +241.56
Nos2 Nitric oxide synthase
U26686.1, RGD ID 3185
+1.82 +169.95 +135.48
Cxcl9 Chemokine ligand 9
NM_145672.4, RGD ID 628798
+3.82 +118.20 +100.95
Il12b Interleukin 12B
NM_022611.1, RGD ID 628704
+1.7 +42.0 +87.7
Cxcl2 Chemokine ligand 2
NM_053647.1, RGD ID 70069
+1.2 +75.4 +67.3
Il1a Interleukin 1 alpha
NM_017019.1, RGD ID 2890
+1.1 +45.3 +57.0
Ccl4 Chemokine ligand 4
NM_053858.1, RGD ID 620441
+3.33 +17.65 +51.0
Cxcl5 Chemokine ligand 5 (also known as Cxcl6)
NM_022214.1, RGD ID 708540
+1.1 +54.9 +43.4
Ccl2 Chemokine ligand 2
NM_031530.1, RGD ID 3645
+2.34 +34.49 +33.27
Ccl7 Chemokine ligand 7
NM_001007612.1, RGD ID 1359152
1.4 +12.4 +14.4
Ccl3 Chemokine ligand 3
NM_013025.2, RGD ID 3647
1.3 +9.1 +11.4
Il6 Interleukin 6
M26744.1, RGD ID 2901
1.1 +5.6 +8.4
Il11 Interleukin 11
NM_133519.4, RGD ID 621475
1.99 +19.28 +7.40
Ptgs2 Prostaglandin endoperoxide synthase 2
NM_017232.3, RGD ID 620349
1.2 +11.8 +7.2
Ccl19 Chemokine ligand 19
NM_001108661.1, RGD ID 1310336
+2.39 +5.21 +6.87
Mbl2 Mannose-binding lectin 2
NM_022704.2, RGD ID 67380
+126.17 +33.22 +6.46
Ccl24 Chemokine ligand 24
NM_001013045.1, RGD ID 1310245
+1.65 +24.55 +6.51
Cxcl10 Chemokine ligand 10
NM_139089.1, RGD ID 620209
+1.8 +4.5 +5.5
Il22ra2 Interleukin 22 receptor, alpha 2
NM_001003404.1, RGD ID 1303169
+1.1 +2.5 +4.0
Il10 Interleukin 10
NM_012854.2, RGD ID 2886
3.97 +3.08 +2.69
Il1rn Interleukin 1 receptor antagonist
NM_022194.2, RGD ID 621159
2.19 +3.76 +2.63
Tlr2 Toll-like receptor 2
NM_198769.2, RGD ID 735138
1.5 +1.8 +2.1
Ccr1 Chemokine receptor 1
NM_020542.2, RGD ID 708446
2.89 +3.88 +1.96
Traf2 Tnf receptor-associated factor 2
NM_001107815.2, RGD ID 1310457
+1.6 +1.9 +1.6
Mknk1 MAP kinase-interacting serine/threonine kinase 1
NM_001044267.1, RGD ID 1559603
+1.4 +1.6 +1.5
CD47 Cluster of diﬀerentiation 47
NM_019195.2, RGD ID 2308
1.1 +1.3 +1.4
Pla2g4a Phospholipase A2, group IVA (cytosolic, Ca-dependent)
NM_133551.2, RGD ID 67366
1.7 +1.7 +1.3
Tlr7 Toll-like receptor 7
EF032637.1, RGD ID 1563357
1.2 +1.8 +1.3
(continued on next page)
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Table 1 (continued)
Gene Name, NCBI reference sequence ID, RGD ID Rosuvastatin LPS LPS+ Rosuvastatin
Ddit3 DNA-damage-inducible transcript 3
NM_001109986.1, RGD ID 62391
1.3 +1.7 +1.3
Il18rap Interleukin 18 receptor accessory protein
XM_003750691.2, RGD ID 727867
+1.2 +1.7 +1.2
Hmgn1 High-mobility group nucleosome-binding domain 1
NM_001013184.1, RGD ID 1307761
+1.6 +1.2 +1.0
Scarb1 Scavenger receptor class B, member 1
NM_031541.1, RGD ID 2302
+1.1 1.3 +1.0
Jun Jun proto-oncogene
NM_021835.3, RGD ID 2943
+1.2 1.8 1.1
Hspb1 Heat shock protein 1
NM_031970.3, RGD ID 61306
+2.79 1.04 1.19
Hc Clathrin, heavy chain
NM_019299.1, RGD ID 2364
+1.0 +1.1 1.3
Tgfb3 Transforming growth factor, beta 3
NM_013174.2, RGD ID 3851
+1.2 1.9 1.4
Elmo1 Engulfment and cell motility 1
NM_001108415.1, RGD ID 1308182
1.0 1.7 1.6
Prkca Protein kinase C, alpha
NM_001105713.1, RGD ID 3395
+1.3 2.1 1.7
Il10rb Interleukin 10 receptor, beta
NM_001107111.1, RGD ID 1560373
1.4 1.1 1.9
Tgfbr1 Transforming growth factor, beta receptor 1
NM_012775.2, RGD ID 3852
1.2 2.5 2.0
Sirpa The signal-regulatory protein a
NM_013016.2, RGD ID 3449
1.5 2.7 2.8
Tlr5 Toll-like receptor 5
FJ750588.1, RGD ID 631351
1.2 3.0 2.9
Ccl11 Chemokine ligand 11
NM_019205.1, RGD ID 3644
1.2 1.4 3.0
Myl2 Myosin, light polypeptide 2
NM_001035252.1 (old), NM_001035252.2,
RGD ID 1564245
1.3 4.4 5.2
The National Center for Biotechnology Information (NCBI) Reference Sequence Database can be retrieved at http://www.ncbi.nlm.nih.gov/refseq/. A description of a gene
function (RGD ID) can be found in The Rat Genome Database 2015 (Shimoyama et al., 2015) at http://rgd.mcw.edu/. Data are expressed as fold-change over the expression
of unchallenged and untreated (control) microglial cells. Treatments had diﬀerent eﬀects on inﬂammation-related genes. LPS mostly induced the upregulation of genes as
compared with the untreated control microglia. Rosuvastatin alone also had some eﬀects on these genes. Combined treatment demonstrated that rosuvastatin had diﬀerent
eﬀects on LPS-activated microglia cells: inhibited the eﬀect of LPS on certain genes (e.g. Ccl24, Ccr1, Kng1, Nos2, Il11), while it had a synergistic eﬀect with LPS on others
(e.g. Cxcl1, Ccl4, Il23r).
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microglia, while it was ineﬀective in inhibiting the basal-
level phagocytosis in unchallenged cells, indicating that
rosuvastatin is a potent inhibitor of this function only in
pro-inﬂammatory situations and does not alter the normal
clearance of cell debris in a healthy tissue. Thus, rosuvas-
tatin could be helpful when excess microglial activity could
harm the nervous tissue.
Cytokines, important immunomodulators in the normal
functioning of the CNS, can be released, among others,
by the microglial cells. Cytokines can also be harmful:
previous studies have shown that neurodegeneration
originating through neuroinﬂammation is often elicited by
activated microglia (McGeer and McGeer, 2003, 2010)
through the release of diﬀerent pro-inﬂammatory cytoki-
nes and chemokines (Hanisch, 2002). High levels of
IL-1b could be observed, for instance, in the vicinity of
amyloid plaques of AD patients (McGeer et al., 1993;
Lindberg et al., 2005; Ghosh et al., 2013), where activated
microglia accumulate (Rodriguez et al., 2014). Previous
studies also suggested that statins reduce levels of some
of the pro-inﬂammatory cytokines (Lindberg et al., 2005;Nakamichi et al., 2006; Veillard et al., 2006) and increase
the anti-inﬂammatory cytokine IL-10 (Scho¨nbeck and
Libby, 2004). As expected, both pro- (IL-1b, TNF-a) and
anti-inﬂammatory cytokines (IL-10) were increased in
LPS-challenged cells as compared with the unchallenged
(control) group. Rosuvastatin did not signiﬁcantly aﬀect
the basal cytokine levels in unchallenged microglia, but
strongly inhibited levels of the pro-inﬂammatory cytokines
IL-1b and TNF-a when tested in LPS-challenged cells.
Besides the inhibition of these pro-inﬂammatory agents,
rosuvastatin exerted a direct anti-inﬂammatory eﬀect by
elevating the level of IL-10 in both unchallenged and
LPS-challenged cells.
Eﬀects of rosuvastatin on such diverse immune
mechanisms of microglia as phagocytosis and cytokine
production indicated a strong likelihood of its
involvement in many other immune system-wide
functions and possible eﬀects on inﬂammation-related
genes. We demonstrated that rosuvastatin, LPS and
their combination had diﬀerential eﬀects on the
expression of inﬂammation-related genes. Several
genes were upregulated after LPS challenge, conﬁrming
Fig. 7. Relative expression levels of various inﬂammation-related genes identiﬁed by real-time PCR in pure microglia cells. Pure microglial cultures
(subDIV4) were maintained and treated as described in Experimental procedures section. The cells (subDIV4) were cultured with or without LPS for
24 h in the presence or absence of rosuvastatin. The extraction of total RNA and the real-time PCR are described in Experimental procedures
section. The transcription levels of the chemokine ligand 24 (Ccl24, A), the chemokine receptor 1 (Ccr1, B), IL-11 (C), the chemokine (CXC motif)
ligand 1 (or melanoma growth-stimulating activity, alpha), (Cxcl1, D), the chemokine ligand 4 (Ccl4, E), the chemokine ligand 5 (Ccl5, F), the heat
shock protein 1 (Hspb1, G), the transforming growth factor beta (TGFbl-2, H) and the mannose-binding lectin (protein C) 2 (Mbl2, I) are shown in
unstimulated (control), LPS-challenged and LPS-challenged + rosuvastatin-treated cells. For some pro-inﬂammatory genes, rosuvastatin inhibited
their expression which was upregulated in LPS-challenged cells. In connection with Cxcl1, Ccl4 and Ccl5, the combined treatment revealed
synergistic eﬀects between rosuvastatin and LPS for Cxcl1, Ccl4 and Ccl5. Rosuvastatin increased levels of expression of Hspb1, TGF-b andMbl2.
Relative expression levels (on a log2 scale) ± SD from at least four separate experiments are shown for each condition. Data were analyzed with a
two-way ANOVA. *p< 0.05; **p< 0.01; ***p< 0.001.
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Rosuvastatin itself and in combination with LPS
displayed diﬀerent eﬀects on gene expression. Although
rosuvastatin was not able to decrease all the LPS-
upregulated genes, it suppressed the pro-inﬂammatory
eﬀects of LPS on some genes such as Ccl24 or Ccr1.
Ccl24 is a chemokine that can readily be upregulated by
pro-inﬂammatory cytokines or microbial stimulus such
as LPS (Watanabe et al., 2002). Ccr1 is implicated in mul-
tiple sclerosis (MS) and experimental autoimmune
encephalomyelitis (EAE). Previous studies suggestedthat Ccr1 could be upregulated in EAE (Rottman et al.,
2000), and the microglia expressed Ccr1 around the
demyelinating plaques, making Ccr1 antagonists or inhibi-
tors possible targets for the development of MS-therapy
(Hesselgesser et al., 1998; Eltayeb et al., 2007).
Rosuvastatin additionally increased the expression of
certain genes. Its general eﬀects on microglia were
predominantly anti-inﬂammatory. The gene most
upregulated by rosuvastatin was Mbl2, which is important
in innate immunity (Worthley et al., 2005; Ip et al., 2009)
and involved in the stimulation of phagocytosis (Stuart
D. Kata et al. / Neuroscience 314 (2016) 47–63 61et al., 2005). Hspb1 was also upregulated by rosuvas-
tatin. Hspb1 is a heat-shock protein with strong
anti-apoptotic potential that regulates the cytoskeleton
dynamics through F-actin stabilization (Concannon
et al., 2003). Cxcl1 has been reported to be an anti-
inﬂammatory protein with a neuroprotective role (Omari
et al., 2009). Additional chemokine genes such as Ccl2
(El Khoury et al., 2007; El Khoury and Luster, 2008),
Cxcl1 (Bosivert et al., 2006) and Ccl5 were all upregulated
in our studies and implicated in microglia recruitment to
areas of inﬂammation. Although Ccl5 has been demon-
strated to induce pro-inﬂammatory mechanisms (Skuljec
et al., 2011), it has also been shown to ameliorate
AD-like pathology by recruiting microglia to b-amyloid
deposits (Lee et al., 2012). The expression of a number
of phagocytosis-related gene was also tested. For
example, Mbl2 was upregulated in rosuvastatin-treated
microglia in a seemingly contradictory action, while
several other genes known to be involved in phagocytosis
were inhibited, as expected from the phagocytosis
essays, by rosuvastatin (for example Myl2 (1.27), Sirpa
(1.50), Elmo1 (1.05), or CD47 (1.07)). Although the
overall downstream eﬀect in the microglia is a strong inhi-
bition of phagocytosis upon rosuvastatin treatment, it
remains to be seen as to what intracellular signalization
is activated to aﬀect these genes or how these genes
interact to elicit this particular cell response.
In summary, rosuvastatin elicits robust changes in the
microglial functions in vitro as it potently inhibits the
harmful pro-inﬂammatory signals and signiﬁcantly
enhances the beneﬁcial anti-inﬂammatory actions of
pure microglial cells after LPS challenge. Its eﬀects
include anti-mitogenic and anti-phagocytic action, strong
inhibition of the synthesis of pro-inﬂammatory cytokines
paralleled by a very strong stimulation of anti-
inﬂammatory cytokine production, and a beneﬁcial
diﬀerential expression of a number of inﬂammation-
related genes. As activated microglia often damage
neuronal tissues by excessive cytokine and chemokine
production and phagocytosis, the strong inhibition of
such pro-inﬂammatory action by rosuvastatin illustrates
an advantageous eﬀect of this drug. Thus, rosuvastatin
may be used prophylactically to inhibit pro-inﬂammatory
and activate anti-inﬂammatory mechanisms of the
microglia in order to reduce neuroinﬂammation and
consequently neurodegeneration substantially. The
microglia could therefore be a novel, speciﬁc therapeutic
target in the ﬁght against neurodegenerative disorders.COMPETING INTERESTS
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